Introduction
The recommended dose of traditional cytotoxic antitumor agents is generally determined at or near their maximum-tolerated dose (1) (2) (3) . However, in the case of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the recommended dose is determined at an optimal biological dose to minimize the risk of adverse events (AEs) without compromising efficacy (4) (5) (6) . However, body size was not taken into consideration in previous dose-finding studies. A significant number of EGFR-mutated patients are female and, in their majority, the body surface area (BSA) may be low (7) (8) (9) . Therefore, a dose reduction due to AEs or low BSA may be required in daily clinical practice for such patients. However, there is limited information on the association between low BSA and TKI dose reduction and efficacy (10) . In addition, the efficacy of TKIs in patients undergoing a dose reduction due to severe AEs has not been clearly determined. In the present study, we evaluated the efficacy of TKIs in patients undergoing a dose reduction due to AEs and in those with a low BSA in clinical practice.
Patients and methods
Patients. A total of 282 consecutive patients with pathologically confirmed non-small-cell lung cancer (NSCLC), who were treated with TKIs at the University of Tsukuba Hospital, the Tsukuba Medical Center Hospital, the Ryugasaki Saiseikai General Hospital and the Mito Medical Center-Mito Kyodo General Hospital between September, 2005 and May, 2013, were retrospectively analyzed. The histopathological diagnoses were performed according to the World Health Organization classification system (11) and the patients were staged according to the Union for International Cancer Control tumor node metastasis staging system (12) .
The patient characteristics, efficacy and safety were evaluated using patient data extracted from the database of each participating institution. (Table III) .
Efficacy of tyrosine kinase inhibitors in non-

BSA and RR, DCR, PFS and OS in EGFR-mutated patients treated with gefitinib.
We compared RR, DCR and PFS between 45 patients with BSA >1.5 m 2 and 37 with BSA <1.5 m 2 . The RR and DCR were 82.2 and 95.6% in the former patient group and 67.6 and 91.9% in the latter group, respectively. There was no statistically significant difference between the two groups (P= 0.196 and 0.645, respectively). There was also no statistically significant difference in the PFS between the two groups of patients (BSA >1.5 m 2 , 12.1 months vs. <1.5 m 2 , 12.8 months; P= 0.861) (Fig. 1) . The OS appeared to be longer in patients with BSA <1.5 m 2 compared to that in patients with >1.5 m 2 , although the difference was not statistically significant (P=0.080).
Dose reduction and RR, DCR, PFS and OS in EGFR-mutated patients treated with gefitinib.
We next evaluated the effect of dose reduction of gefitinib on RR, DCR, PFS and OS. There were 19 patients with and 63 without a dose reduction of gefitinib. The RR and DCR were 78.9 and 94.7% in the former group of patients and 74.6 and 93.7% in the latter group, respectively. There was no statistically significant difference between the two groups (P= 0.699 and 0.862, respectively). As shown in Fig. 2 , there was also no statistically significant difference in PFS between patients with and those without dose reduction (12.1 vs. 12.3 months, respectively; P= 0.522). There appeared to be a difference in OS between patients with and those without dose reduction, but the difference was not statistically significant (P=0.154). The association among BSA, dose reduction of gefitinib, PFS and OS is shown in Fig. 3 . Of the 24 patients with BSA <1.5 m 2 , 22 (91.7%) were female, 13 (54.2%) were aged ≥75 years, 10 (41.7%) underwent a dose reduction and 19 (79.2%) received no further cytotoxic antitumor chemotherapy. There were no statistical differences among these variables.
BSA and RR, DCR, PFS and OS in patients treated with erlotinib.
In the 14 EGFR-mutated patients treated with erlotinib, there was no statistically significant difference in RR, DCR and PFS between those with and those without dose reduction (RR: 87.5 vs. 50%, P= 0.124; DCR: 100 vs. 89.3%, P= 0.230; and PFS: 14.3 vs. 8.0 months, P=0.409).
In the 39 wild-type EGFR patients treated with erlotinib, there was no statistically significant difference in PFS between those with and those without dose reduction (P=0.794). There was no apparent statistical difference in OS between patients with a BSA of >1.5 and those with a BSA of <1.5 m 2 (P= 0.589). However, there was a statistically significant difference in OS between those with and those without dose reduction (P=0.172).
Discussion
Previous clinical trials reported that using a fixed dose of EGFR-TKIs achieved a significant improvement in PFS with acceptable AE profiles (14, 15) . Either gefitinib or erlotinib are currently among the first-choice treatments for advanced NSCLC patients with EGFR mutation (14, 15) . However, the efficacy of TKIs in the clinical setting, particularly in patients undergoing a dose reduction due to toxicity or low BSA, remains unclear. There remained the question whether a strictly fixed dose of TKIs, determined by dose-finding studies, would exhibit the same efficacy in patients undergoing a dose reduction as in those without a dose reduction. Therefore, we evaluated RR, DCR, PFS and OS in patients with and those without dose reduction of TKIs. In the present study, clinically relevant AEs >grade 3 were observed in 23 (8.2%) of the 282 patients, leading to a dose reduction in 11 of the patients. Therefore, 42 patients underwent a dose reduction due to reasons other than AEs. In addition, 46.4% of the 282 patients had a BSA of <1.5 m 2 , demonstrating that a considerable percentage of patients with low BSA received TKI therapy, which may be associated with the fact that a number of those patients were EGFR-mutated female patients. In fact, in previous reports on treatment with TKIs, either in clinical trials or clinical practice, there was a higher population of female patients with NSCLC compared to that in the general population (7) (8) (9) 16) .
Our study did not identify any disadvantage regarding PFS from a dose reduction in patients receiving gefitinib or erlotinib. However, as these findings were obtained from a relatively small number of patients in a retrospective study, we were unable to draw definitive conclusions on how dose reduction would affect patients with AEs and those with low BSA. We recommend that our results be meaningfully interpreted rather than be overlooked as anecdotal findings. We may need to reconsider the most appropriate dosage of TKIs for such patients, in order to obtain maximum efficacy with an acceptable toxicity profile.
To the best of our knowledge, there has been only one previous study evaluating the effect of BSA on the efficacy of TKIs (10) . That study investigated the potential effect of BSA on the PFS and OS of patients with advanced EGFR-mutated NSCLC who were treated with gefitinib (10) and found that BSA affected the outcome of gefitinib therapy, with a higher BSA being associated with worse PFS (10) . The main focus of that study was treatment efficacy in patients with a high BSA; by contrast, our interest was not only the effects of dose reduction in patients with AEs as well as in patients with a low BSA. In the previous study, the PFS of patients with low BSA with treatment interruption or reduced dose was either equal to or superior to that of all low-BSA patients (10) , which was consistent with our results. Ichihara et al (10) hypothesized that the patients who required a dose reduction due to AEs may be those with relatively high blood concentrations of the agent, due to factors such as drug metabolism. This hypothesis requires confirmation in future studies.
Another point investigated was the effect of BSA on OS. Ichihara et al (10) reported that OS was not associated with BSA in their study. In our study, there was no apparent difference in OS between patients with BSA <1.5 m 2 and those with BSA >1.5 m 2 receiving treatment with either gefitinib or erlotinib. The OS in patients without dose reduction appeared to be longer compared to that in patients with dose reduction, but the difference was not statistically significant. As suggested by Ichihara et al (10) , a possible reason may be the effect of preceding and/or subsequent therapies on OS. In their study, as many as 70% of the patients received chemotherapy following disease progression post-gefitinib monotherapy, suggesting that post-progression therapy may have blunted any difference in PFS between the high-and low-BSA subgroups (10) . Another explanation for these results may be the fact that further cytotoxic antitumor chemotherapy was not indicated in the majority of the low-BSA patients, as observed in our study. We were unable to identify a statistically significant difference in dose reduction for patients with low BSA. The analysis of our data set and conclusions drawn were limited by the small sample size, retrospective design and heterogeneity in the EGFR mutations, TKIs used, clinicians' experience with TKIs, reasons for dose reduction and exclusion of patients with discontinuation of TKIs without any dose reduction. Another major limitation is that pharmacokinetic data were not included in this analysis. It remains unclear whether BSA differences led to inter-patient pharmacokinetic variability, resulting in the observed difference in PFS. A pharmacokinetics-pharmacodynamics study is required to clarify this issue. The blood concentration of cytotoxic agents is closely associated with their efficacy (17) (18) (19) . Similarly, the blood concentration of TKIs also appears to be associated with their efficacy (20, 21) . Dose-reduction estimation studies for TKIs may be crucial, particularly for patients with low BSA. Heterogeneity in these factors should be taken into consideration, or exclude causes of heterogeneity. Prospective studies investigating the incidence of dose reduction in patients with AEs and those with low BSA may be meaningful for common clinical practice. This approach may further elucidate the clinical meaning of dose reduction of TKIs in such patients.
